Relmada Therapeutics
NASDAQ: RLMDNew York, US · Founded 2012 · Nevada corporation · 15 known investors
Find your way into Relmada Therapeutics
136 people in our graph share verified history with the Relmada Therapeutics team — schools, employers, funds. One of them is your warm intro.
Michael Taylorunlockedknows Eliseo O. Salinas · together at Wyeth Pharmaceuticals (overlapped)
×9knows the team · via Wyeth Pharmaceuticals
×2knows the team · via Elan Pharmaceuticals
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation. Its programs address indications such as bladder cancer and Prader-Willi syndrome.
Founders & leadership
ST
Sergio TraversaExecutive
PK
Paul KellyExecutive
MS
Maged ShenoudaExecutive
EO
Eliseo O. SalinasinPresident & Chief Scientific Officer2014–2015Eliseo Salinas is President and Chief Scientific Officer of Relmada Therapeutics, a clinical-stage biopharmaceutical company. He brings over 25 years of experience in biotech and pharmaceutical drug development, with involvement in numerous FDA approvals and clinical development programs.
DB
Douglas BeckChief Financial Officer
CE
Charles EnceChief Accounting and Compliance Officer
CC
Charles CasamentoNamed on SEC filing
Board
SS
Sandesh SethLead Director
SA
Shreeram AgharkarBoard director
NM
Nabil M. YazgiBoard director
Investors · 15
BioAdvanceConshohocken · $500K – $1.5M
BAM ElevatereportedChicago
BraidwellreportedStamford
Commodore CapitalreportedNew York
Janus Henderson InvestorsreportedLondon
OrbiMedreportedNew York · $1M – $75M
RA CapitalreportedBoston
VenrockreportedPalo Alto · $500K – $10M
Venrock Healthcare Capital PartnersreportedNew York
Also in the syndicate · 6
Columbia Threadneedle InvestmentsEventide Asset ManagementGreat Point PartnersJanus HendersonSpruce Street CapitalSquadron Capital Management
Funding
SEC filings, press & company announcements$211.1M disclosed across 8 of 10 rounds · 1900–2026
- $160MraisedMar 2026 · 2 sources
Adage Capital Management, Balyasny Asset Management, Braidwell LP, Columbia Threadneedle Investments, Commodore Capital, Eventide Asset Management, Great Point Partners, Janus Henderson, Janus Henderson Investors, Marshall Wace, OrbiMed, RA Capital, Spruce Street Capital, Squadron Capital Management, Venrock, Venrock Healthcare Capital Partners
Source ↗
▶$825.8KraisedOct 2019 · 7 investors · BiotechnologyRule 506(b)
▶$825.8KraisedOct 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maged ShenoudaDirector
- Ottavio VitoloExecutive Officer
- Paul KellyDirector
- Charles CasamentoDirector
- Chuck EnceExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Offering amount
- $825.8K
- Amount sold
- $825.8K
- Minimum investment
- $10K
- First sale
- Sep 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$8.4MraisedJul 2019 · 116 investors · BiotechnologyRule 506(b)
▶$8.4MraisedJul 2019 · 116 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles CasamentoDirector
- Sergio TraversaExecutive Officer, Director
- Ottavio VitoloExecutive Officer
- Paul KellyDirector
- Maged ShenoudaDirector
- Offering amount
- $10M
- Amount sold
- $8.4M
- Minimum investment
- $10K
- Sales commissions
- $688.9K
- Placement agents
- Brookline Capital Markets, A division of Arcadia Securities, LLC, Alexander Capital, LP
- First sale
- Jun 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.4MraisedMay 2019 · 43 investors · BiotechnologyRule 506(b)
▶$3.4MraisedMay 2019 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergio TraversaExecutive Officer, Director
- Charles CasamentoDirector
- Ottavio VitoloExecutive Officer
- Maged ShenoudaDirector
- Paul KellyDirector
- Offering amount
- $10M
- Amount sold
- $3.4M
- Minimum investment
- $10K
- Sales commissions
- $221.2K
- Placement agents
- Alexander Capital, LP, Brookline Capital Markets, A division of CIM Securities, LLC
- First sale
- May 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.8MraisedDec 2018 · 66 investors · BiotechnologyRule 506(b)
▶$5.8MraisedDec 2018 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul KellyDirector
- Ottavio VitoloExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Maged ShenoudaDirector
- Charles CasamentoDirector
- Offering amount
- $10M
- Amount sold
- $5.8M
- Minimum investment
- $10K
- Sales commissions
- $563.9K
- Placement agents
- Alexander Capital, LP
- First sale
- Oct 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6.9MraisedOct 2017 · 65 investors · BiotechnologyRule 506(b)
▶$6.9MraisedOct 2017 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergio TraversaExecutive Officer, Director
- Charles CasamentoDirector
- Paul KellyDirector
- Maged ShenoudaDirector
- Offering amount
- $6.9M
- Amount sold
- $6.9M
- Minimum investment
- $5K
- Sales commissions
- $584.5K
- Placement agents
- Alexander Capital, LP
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$10.7MraisedJun 2014 · 236 investors · BiotechnologyRule 506(b)
▶$10.7MraisedJun 2014 · 236 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nabil M. YazgiDirector
- Douglas BeckExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Shreeram AgharkarDirector
- Sandesh SethDirector
- Eliseo O. SalinasExecutive Officer
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- Minimum investment
- $100K
- Sales commissions
- $1.1M
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Jun 2014
- Incorporated
- Corporation, Nevada, 2012
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2014 · 382 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2014 · 382 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BeckExecutive Officer
- Sergio TraversaExecutive Officer, Director
- Sandesh SethDirector
- Eliseo O. SalinasExecutive Officer
- Nabil M. YazgiDirector
- Shreeram AgharkarDirector
- First sale
- May 2014
- Incorporated
- Corporation, Nevada, 2012
- Federal exemptions
- 06b
▶$15.1MraisedMay 2014 · 225 investors · BiotechnologyRule 506(b)
▶$15.1MraisedMay 2014 · 225 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eliseo O. SalinasExecutive Officer
- Douglas BeckExecutive Officer
- Sandesh SethDirector
- Shreeram AgharkarDirector
- Nabil M. YazgiDirector
- Sergio TraversaExecutive Officer, Director
- Offering amount
- $15.1M
- Amount sold
- $15.1M
- Minimum investment
- $100K
- Sales commissions
- $1.8M
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Relmada (RLMD) Q2 2026 Earnings Call Transcript | The Motley Foolfool.com · Aug 2026
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 pathstocktitan.net · Aug 2026Frequently asked questions
- What does Relmada Therapeutics do?
- Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation. Its programs address indications such as bladder cancer and Prader-Willi syndrome.
- Who are Relmada Therapeutics's investors?
- Relmada Therapeutics's investors include BioAdvance, BAM Elevate, Braidwell, Commodore Capital, Janus Henderson Investors, OrbiMed, RA Capital, Venrock and 1 more.
- How much funding has Relmada Therapeutics raised?
- Relmada Therapeutics has disclosed $211.1M raised across 8 of its 10 known rounds.
- Where is Relmada Therapeutics headquartered?
- Relmada Therapeutics is headquartered in New York, US.